Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. - Wikidata - wikimedia - TriplyDB

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.

http://www.wikidata.org/entity/Q30535328

about

Recent advances in understanding and managing cholestasis Novel bile acid therapeutics for the treatment of chronic liver diseases Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management Role of the intestinal bile acid transporters in bile acid and drug disposition Cystic fibrosis related liver disease--another black box in hepatology.Clinical application of transcriptional activators of bile salt transporters.Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation.Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver Fibrosis 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in mice Nuclear receptors as drug targets in cholestatic liver diseases.Primary sclerosing cholangitis: diagnosis, prognosis, and management.High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.Hepatic inflammation and progressive liver fibrosis in chronic liver disease.Treatment options for primary sclerosing cholangitis.Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis.Evolving concepts in primary sclerosing cholangitis.Primary sclerosing cholangitis: is any treatment worthwhile?Recent insights in primary sclerosing cholangitis.Molecular targets for the treatment of fibrosing cholangiopathies.Bile acid transporters and regulatory nuclear receptors in the liver and beyond Primary sclerosing cholangitis: a review and update on therapeutic developments.Primary Sclerosing Cholangitis: Current and Future Management Strategies.Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis.Animal models in primary biliary cirrhosis and primary sclerosing cholangitis.Primary sclerosing cholangitis - the Norwegian experience.Primary biliary cirrhosis: safety and benefits of established and emerging therapies.Emerging treatments for primary sclerosing cholangitis.Management of cholestatic disease in 2017.Role of farnesoid X receptor in cholestasis.New therapeutic concepts in bile acid transport and signaling for management of cholestasis.Animal models of biliary injury and altered bile acid metabolism.The human UGT1A3 enzyme conjugates norursodeoxycholic acid into a C23-ester glucuronide in the liver.High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?Ursodeoxycholic acid stabilizes the bile salt export pump in the apical membrane in MDCK II cells.Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis.Primary sclerosing cholangitis: diagnostic and management challenges.Bile acid metabolism in liver pathobiology.Primary Sclerosing Cholangitis

P2860

Q26748537-51CD2FB7-D5AC-4002-BD7C-4BE4142E8D43 Q26748613-B231FFE2-9404-452C-A593-821BAAD04398 Q26800206-81AB49E4-9C96-4487-9FEA-27FE72FC8D2C Q27015831-5BFE7615-93B0-4C2D-8B63-31ED91171734 Q28299162-1709E946-6443-451F-B3B0-31F59DAC6FE0 Q28655881-33AAA3A1-8CB7-40D5-A641-70F529D940DB Q33709930-8E85E2F0-BDE5-4F67-90A7-DB709F6B7590 Q34043010-83E4E164-7EF0-4C3F-A1DF-BA7A2B8D0845 Q34983463-C036EE46-30B8-491A-81E1-954050642DC3 Q35201779-170AA1E5-115C-44A9-9440-BE100595CA8C Q35269164-582BDC41-AED2-4C1D-B7D8-4F4205ABBF87 Q36786270-F793B63C-D5D6-4F00-AE64-57469619D716 Q36955053-49A26CCA-754D-4D94-B891-3559CCE0FEDD Q37117971-059D6D7B-8839-46F2-BB1E-CDF40811BE30 Q37629675-C7E981EF-ABA6-4F83-B949-AB3ED0AE956F Q37777156-A5884924-6018-4DD2-BD49-EF2ED692A9A2 Q37866339-17A54D5B-DD61-41C9-9F1E-1A5957DF60A1 Q37957967-01049831-97F7-4C59-9C89-E0C12FC93AA5 Q37962395-C4EF640A-0BF6-4C9F-BD7F-2F3377368A5A Q38019989-F8E40C2D-3AB4-4EC4-998A-8FBA98EA5870 Q38031095-72EB64F3-58EA-47AA-A499-376A458C658F Q38033967-73E8B344-FD01-48F8-A837-20FBAE0ECFBE Q38077820-81E10FAB-2E30-40BF-9871-A0E43AF79411 Q38107484-5C497CA2-45E4-4549-9929-00B143462780 Q38174167-DE09DB40-6303-4B08-B817-7D0B5A3521E2 Q38244716-F634D076-57B3-4E77-B659-B5FA962AA8CB Q38417642-ACCE10FB-CB87-4412-85B8-A7E4DB7A671B Q38554677-AE1A349E-B4C7-429F-95A0-E219193A06AA Q38748384-9009B089-4318-4D48-962E-C70BE6C674D2 Q38774857-A7B5983D-3E4A-40BE-A1D7-2A1F36F8FED9 Q38887864-8BFF7073-CEDD-45FE-9715-398401738437 Q39044702-D2B79109-B25D-4D53-A39B-8F1A6E0BD156 Q39436033-AE4EE3CA-7470-4AC7-8E82-3388748D14C4 Q39779007-5C48B333-1192-4891-A6DF-9F714BF7568D Q43284332-137C53C7-5347-4AA5-9EA2-A230613E67D2 Q45125133-B3B9C1F0-2972-427D-BF1B-182E9AF78ED7 Q45993134-179E6BDD-57CC-4DB9-A848-AB8430FF9100 Q47112995-56476EDE-2355-499E-8248-502F53D98982 Q47645986-F8DE75EC-5082-49EB-8E46-421AC4A0A977 Q56442935-4625A0F8-19CF-4A5D-B022-D569CC6BA3FB

P2860

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.

http://www.wikidata.org/entity/Q30535328

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Side chain structure determine ...... xycholic acid in Mdr2-/- mice.

@ast

Side chain structure determine ...... xycholic acid in Mdr2-/- mice.

@en

type

label

Side chain structure determine ...... xycholic acid in Mdr2-/- mice.

@ast

Side chain structure determine ...... xycholic acid in Mdr2-/- mice.

@en

prefLabel

Side chain structure determine ...... xycholic acid in Mdr2-/- mice.

@ast

Side chain structure determine ...... xycholic acid in Mdr2-/- mice.

@en

P1433

Q30535328-B97556D9-E215-4C82-8A37-8E2DE5528C9F

P1476

Q30535328-2F365432-52B7-4E56-BA74-144C7F4437AA

P2093

Q30535328-0FAFB6ED-DE36-44A5-B2E9-44F1798C8555

Q30535328-128ACE30-691D-4B06-AC49-314A353BFA2F

Q30535328-64E577E6-6FCE-45A0-96C5-86AF3A4902D1

Q30535328-71A822E8-9EE6-4292-9F43-22DAD0B352C7

Q30535328-7D6B3443-823B-412C-A4DA-FA74E3A29EDB

Q30535328-969C0448-4362-47AE-B1CB-F52CA6810771

Q30535328-A8870732-AEA5-4697-9C3F-3B50C15A57A3

Q30535328-AECB5A46-B0CA-4069-8E97-5D9AA37AD5F1

Q30535328-BF38D9C6-F3D2-4661-9E98-D783D2C1BF73

Q30535328-BFF03EFF-72C6-49D5-929A-A7B4EDAB77D2

P2860

Q30535328-21544384-473A-4A7C-9C07-E3DEB6CE23A0

Q30535328-257B9EBE-54E9-44AA-9D68-A3BB49B0A6BE

Q30535328-2F4C388A-59C4-4F99-8810-A2711520C12A

Q30535328-433EB3BC-3225-45D1-9C36-8BD305942427

Q30535328-4BE65D1F-6FA6-4A6D-981C-AF97A55DAFCC

Q30535328-5C83AA95-2A0F-4E4F-89D5-E855AC133197

Q30535328-642377B6-26AB-419F-8479-1B29C628EE1E

Q30535328-6682EDAF-CC73-48DE-B4D6-0F819DCC65DE

Q30535328-67FCBC4A-C288-43CF-B7B5-97E12FE61A0D

Q30535328-6A6ED7F1-34F1-423F-89DE-0304FA6F7E8F

P304

Q30535328-C2359AAE-2E98-43EB-99CD-BA8419687E54

P31

Q30535328-9F447983-391F-4CAA-8C74-110D461C6412

P356

Q30535328-FD589640-17B2-40DC-B674-2EFEEEC64BA7

P407

Q30535328-26AFC25E-DAD5-44AD-9EAF-0DA7471719E2

P433

Q30535328-DAC90B7E-8828-4A9D-9C34-AA5C4DCF681A

P478

Q30535328-C9C9C156-3102-4660-A3C6-4D6B7ECB03D9

P50

Q30535328-67800C8F-B268-4F80-833C-2BBF5CFAB3F6

Q30535328-9B1BB786-9ACD-427F-BF35-135AF49F6A5D

Q30535328-AF151BBA-48C9-49D4-AFC0-D2CB1884D705

P577

Q30535328-DB7C2A4A-E871-4797-A019-90B31C17550F

P5875

Q30535328-E7D983EF-6E90-417F-BA6F-6C5A32FE6FE4

P698

Q30535328-AAF307B8-A6CF-41AE-AE24-CCEB88FFE255

P932

Q30535328-5E7C70DE-EA11-460E-9D1F-7F776758445C

P356

P1433

P1476

Side chain structure determine ...... xycholic acid in Mdr2-/- mice.

@en

P2093

Alan F Hofmann

http://www.w3.org/2001/XMLSchema#string

Andrea Fuchsbichler

http://www.w3.org/2001/XMLSchema#string

Carlo Spirli

http://www.w3.org/2001/XMLSchema#string

Cord Langner

http://www.w3.org/2001/XMLSchema#string

Dagmar Silbert

http://www.w3.org/2001/XMLSchema#string

Emina Halilbasic

http://www.w3.org/2001/XMLSchema#string

Hanns-Ulrich Marschall

http://www.w3.org/2001/XMLSchema#string

Helmut Denk

http://www.w3.org/2001/XMLSchema#string

Judith Gumhold

http://www.w3.org/2001/XMLSchema#string

Mario Strazzabosco

http://www.w3.org/2001/XMLSchema#string

P2860

A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis

An animal model for cystic fibrosis made by gene targeting.

Isolation of small polarized bile duct units.

Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations.

The cholangiopathies: disorders of biliary epithelia.

MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes.

Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes.

Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis.

Proinflammatory cytokines inhibit secretion in rat bile duct epithelium.

Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.

P304

1972-1981

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.22891

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26246984

http://www.w3.org/2001/XMLSchema#string

P698

19475687

http://www.w3.org/2001/XMLSchema#string

P932

3569724

http://www.w3.org/2001/XMLSchema#string